Verastem, Inc. (NASDAQ:VSTM) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Verastem Oncology's Third Quarter 2025 Earnings Conference Call. My name is Liz, and I'll be your call operator for today.
Verastem Inc. (VSTM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Balyasny Asset Management Dmitry Balyasny | 4,146,762 | $36,615,908 | -2% | 0.05% |
| 2. | Logos Capital Arsani William | 4,050,000 | $35,761,500 | +305% | 3.21% |
| 3. | Point72 Asset Management Steve Cohen | 3,879,364 | $34,254,784 | 0.06% | |
| 4. | Stonepine Capital Timothy P. Lynch | 2,670,032 | $23,576,383 | +97% | 19.17% |
| 5. | Vivo Capital Albert Cha And Frank Kung | 2,644,985 | $23,355,218 | +72% | 1.88% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.84 | 2,000 | $7,680.00 | 2,000 | 2017-09-05 | Filing | |
| $2.17 | 50,000 | $108,500.00 | 218,000 | 2020-12-04 | Filing | |
| $3.21 | 33,000 | $105,930.00 | 168,000 | 2019-03-15 | Filing | |
| $7.31 | 5,000 | $36,550.00 | 135,000 | 2018-09-28 | Filing | |
| $7.30 | 3,000 | $21,900.00 | 10,700 | 2018-09-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.16 | 10,321 | $73,898.36 | 400,104 | 2026-01-12 | Filing | |
| $7.16 | 5,039 | $36,079.24 | 104,719 | 2026-01-12 | Filing | |
| $7.86 | 80 | $628.80 | 109,758 | 2025-12-24 | Filing | |
| $9.14 | 592 | $5,410.88 | 101,147 | 2025-12-16 | Filing | |
| $9.14 | 393 | $3,592.02 | 410,425 | 2025-12-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 174,384 | $1,346,244 | 0.05% | |
| 2. | 390,325 | $3,013 | 0% | |
| 3. | 143 | $1,104 | 0% | |
| 4. | 107 | $826 | 0% | |
| 5. | 27 | $208 | 0% |
News See All
Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment
Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc.
Top 8 Long-Term Biotechnology Stocks to Buy
Momentum in biotechnology stocks is accelerating after years of underperformance.
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects
Verastem, Inc. (NASDAQ:VSTM), operating from its headquarters in Massachusetts, is a development-stage biopharmaceutical company.
11 Best Short Squeeze Stocks to Buy Now
The latest U.S. tariff wave has created a suitable environment where short squeeze investments will thrive.
Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Rebecca, and I will be your conference operator today.
5 Best Medical Stocks Under $5
Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company that is involved in the development of drugs for advanced blood cancers.
10 Long-Term Stocks to Buy During Recessions
In this article, we discuss the 10 long-term stocks to buy during recessions.
Hedge Fund and Insider Trading News: Catherine Wood, Dan Loeb, Ray Dalio, Millennium Management, Chessica LP, Incyte Corporation (INCY), Verastem, Inc. (VSTM), and More
Billionaire investor Ray Dalio has said the Federal Reserve's tightening of monetary policy in 2022 shouldn't derail the economic expansion, but is likely to weigh heavily on "bubble-type" tech stocks...
Hedge Fund Resource Center Billionaire Hedge Funds
